Given the association between abdominal obesity and reduced GH secretion, however, augmentation of GH may be one effective strategy to address NAFLD/NASH in those with NAFLD who also exhibit obesity or excess abdominal adiposity. This evidence concerns the gene GH1 and obesity due to melanocortin 4 receptor deficiency.